BMC Cancer 2009, 9:398 http://www.biomedcentral.com/1471-2407/9/398 14. Pommier Y, Fesen MR, Goldwasser F: Cancer chemotherapy and Biotherapy: Principles and practice. 2nd edition. Edited by: Chabner BA, Longo DL. Lippincott-Raven Publishers, Philadelphia; 1996:435-461. 15. Li TK, Liu LF: Tumor cell death induced by topoisomerase-tar- geting drugs. Annu Rev Phamacol Toxicol 2001, 41:53-77. 16. Wilstermann AM, Osheroff N: Base excision repair intermedi- ates as topoisomerase II poisons. J Biol Chem 2001, 276:17727-17731. 17. Kreuzer KN, Cozarrelli NR: Escherichia coli mutants hermo- sensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bac- teriophage growth. J Bacteriol 1979, 140:424-435. 18. Andoh T, Ishida R: Catalytic inhibitors of DNA topoisomerase II. Biochem Biophys Acta 1998, 1400:155-171. 19. Osheroff N: Effect of antineoplastic agents on the DNA cleav- age/religation reaction of the eukaryotic topoisomerase II: inhibition of DNA relegation by etoposide. Biochemestry 1989, 28:6157-6160. 20. Robinson MJ, Osheroff N: Effects of antineoplastic drugs on the poststrand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 1991, 30:1807-1813. 21. Long BH: Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Seminars in Oncology 1992, 19:3-19. 22. Kingma P, Osheroff N: The response of eukaryotic topoisomer- ases to DNA damage. Biochem Biophys Acta 1998, 1400:223-232. 23. Wang JC: DNA topoisomerases. Annu Rev Biochem 1985, 54:665-697. 24. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J: The antican- cer drugs. Oxford University Press, New York; 1996. 25. van Maanem JM, Lafleur MV, Mans DR, Aker E van den, Ruiter C, Koostra PR, Pappie D, De Vries J, Retél J, Pinedo HM: Semiquinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free Radic Res Commun 1998, 4(6):371-84. 26. Kalyanaraman B, Nemec J, Sinha BK: Characterization of free rad- icals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR study. Biochemistry 1989, 30:4839-46. 27. Kagan VE, Yalowich JC, Day BW, Goldman R, Gantchev TG, Stoy- anovsky DA: Ascorbate is the primary reductant of the phe- noxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Biochemistry 1994, 33:9651-60. 28. Walles SAS, Zhou R, Liliemark E: DNA damage induced by etoposide; a comparison of two different methods for deter- mination of strand breaks in DNA. Cancer Lett 1996, 105:153-159. 29. Rojas E, López MC, Valverde M: Single cell gel electrophoresis assay: methodology and applications. J Chromatography B 1999, 722:225-254. 30. Tice R, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki FC: Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000, 35:206-221. 31. Rogers SG, Weiss B: Cloning of the exonuclease III gene of Escherichia coli. Gene 1980, 11:187-195. 32. Hartman A, Speit G: The contribution of cytotoxicity to DNA- effects in the single cell gel test (comet assay). ToxicolLett 1997, 90(2-3):183-8. 33. Rojas E, Valverde M, Kala SV, Kala G, Lieberman MW: Accumula- tion of DNA damage in the organs of mice deficient in γ- glutamyl transpeptidase. Mutat Res 2000, 447:305-316. 34. Gedik CM, Boyle SP, Wood SG, Vaughan NJ, Collins AR: Oxidative stress in humans: validation of biomarkers of DNA damage. Carcinogenesis 2002, 23(9):1441-1446. 35. Cortés-Gutiérrez EI, Dávila-Rodríguez MI, López-Fernández C, Fern- ández JL, Gosálvez J: Alkali-labile sites in sperm cells from Sus and Ovis species. Int J Androl 2008, 31(3):354-363. 36. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996, 73:1518-1524. 37. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA: Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II α1. Canc Res 1998, 58:5298-5300. 38. Negri C, Chiesa R, Cerino A, Bestagno M, Sala C, Zini N, Maraldi NM, Astaldi RG: Monoclonal antibodies to human DNA topoi- somerase I and the two isoforms of DNA topoisomerase II: 170 and 180 kDa isozymes. Exp Cell Res 1992, 200:452-459. 39. Stacey DW, Hitomi M, Chen G: Influence of cell cycle and onco- gene activity upon topoisomerase IIα expression and drug toxicity. Mol Cell Biol 2000, 20:9127-9137. 40. Olive PL, Banath JP: Growth fraction measured using the comet assay. Cell Prolif 1992, 25:447-457. 41. Fortini P, Raspaglio G, Falchi M, Dogliotti E: Analysis of DNA alkylation damage and repair in mammalian cells by the comet assay. Mutagenesis 1996, 11:169-75. 42. Horvátová E, Slamenová D, Hlinciková L, Kumar-Mandal T, Gábelová A, Collins AR: The nature and origin of DNA single-stranded breaks determined with the comet assay. Mut Res 1998, 409:163-171. 43. Ritov VB, Goldman R, Stoyanovsky DA, Menshikova EV, Kagan VE: Antioxidant paradoxes of phenolic compounds: peroxyl rad- ical scavenger and lipid antioxidant, etoposide, inhibits sar- coplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical. Arch Biochem Biophys 1995, 321:140-52. 44. Tyurina YY, Tyurin VA, Yalowich JC, Quinn PJ, Claycamp HG, Schnor NF, Pitt BR, Kagan VE: Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants. Toxicol Appl Pharma- col 1995, 131:277-88. 45. Gantchev TG, van Lier JE, Stoyanovsky DA, Yalowich JC, Kagan VE: Interactions of phenoxyl radical of antitumor drug, etopo- side, with reductants in solution and in cell and nuclear homogenates: electron spins resonance and high-perform- ance liquid chromatography. Methods in Enzymology 1994, 234:631-643. 46. Tornov VA, Konoplyannikov MA, Nikolskaya TA, Konstantinov EM: Apoptosis of unstimulated human lymphocytes and DNA strand breaks in topoisomerase II inhibitor etoposide (VP16). Biochemistry 1999, 64:345-352. 47. Prosperi E, Negri C, Marchese G, Ricotti GC: Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating human lymphocytes. Cell Prolif 1994, 27:257-267. 48. Nouspikel T, Hanawalt PC: DNA repair in terminally differenci- ated cells. DNA repair 2002, 1:59-75. 49. Wenzel U, Nickel A, Kuntz S, Daniel H: Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scav- enging mitochondrial superoxide anions. Carcinogenesis 2004, 25(5):703-712. 50. Liu WM, Oackley PR, Joel SP: Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. Leukemia 2002, 16:1705-1712. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/9/398/pre pub Page 9 of 9 (page number not for citation purposes)